Net cash used in operating activities was $11.05 million for the six months ended June 30, 2026, down from the prior-year period.
Actinium reiterated plans to report data for ATNM-400, Actimab-A for MDSCs and Iomab-ACT in 4Q 2026 and through 2027, with its manufacturing facility expected operational in 2H 2026.
Quarterly financial results
Actinium Pharmaceuticals swung to GAAP net income of $27.9 million in the quarter ended June 30, 2026, from a net loss a year earlier.
Revenue was unchanged at no revenue, while total revenue was $35 million on recognition of previously deferred Immedica license revenue.
R&D expense, net of reimbursements, rose 10.21% to $5.38 million, while general and administrative costs fell 21.57% to $2.06 million.
ATNM•
